$251.56
8.953.69%
At close: -
$250.50
-1.06-0.42%
After Hours: Apr 25, 7:46 PM EDT
Comments
Loading...
Alnylam Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:ALNY | Benzinga
Alnylam Pharmaceuticals Inc has a consensus price target of $314.76 based on the ratings of 26 analysts. The high is $500 issued by HC Wainwright & Co. on April 2, 2025. The low is $159 issued by Leerink Partners on June 25, 2024. The 3 most-recent analyst ratings were released by Morgan Stanley, Needham, and HC Wainwright & Co. on April 11, 2025, April 9, 2025, and April 2, 2025, respectively. With an average price target of $362.67 between Morgan Stanley, Needham, and HC Wainwright & Co., there's an implied 44.78% upside for Alnylam Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Morgan Stanley
Needham
HC Wainwright & Co.
Scotiabank
Redburn Atlantic
1calculated from analyst ratings
Analyst Ratings for Alnylam Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/11/2025 | Buy Now | 6.99% | Morgan Stanley | Michael Ulz61% | $284 → $268 | Maintains | Equal-Weight | Get Alert |
| 04/09/2025 | Buy Now | 27.74% | Needham | Joseph Stringer51% | $320 → $320 | Reiterates | Buy → Buy | Get Alert |
| 04/02/2025 | Buy Now | 99.6% | HC Wainwright & Co. | Patrick Trucchio45% | $500 → $500 | Reiterates | Buy → Buy | Get Alert |
| 03/31/2025 | Buy Now | 36.53% | Scotiabank | Greg Harrison43% | $338 → $342 | Maintains | Sector Outperform | Get Alert |
| 03/31/2025 | Buy Now | 40.92% | Redburn Atlantic | Joshua Smith 34% | → $353 | Initiates | → Buy | Get Alert |
| 03/31/2025 | Buy Now | 37.72% | Stifel | Paul Matteis41% | $300 → $345 | Maintains | Buy | Get Alert |
| 03/24/2025 | Buy Now | 30.94% | JP Morgan | Jessica Fye64% | $280 → $328 | Upgrade | Neutral → Overweight | Get Alert |
| 03/21/2025 | Buy Now | 40.12% | Citigroup | David Lebovitz64% | $338 → $351 | Maintains | Buy | Get Alert |
| 03/21/2025 | Buy Now | 55.69% | Canaccord Genuity | Whitney Ijem47% | $385 → $390 | Maintains | Buy | Get Alert |
| 03/21/2025 | Buy Now | 31.74% | RBC Capital | Luca Issi39% | $310 → $330 | Maintains | Outperform | Get Alert |
| 03/21/2025 | Buy Now | 34.93% | Scotiabank | Greg Harrison43% | $300 → $338 | Maintains | Sector Outperform | Get Alert |
| 03/21/2025 | Buy Now | 14.57% | Wells Fargo | Tiago Fauth43% | $275 → $287 | Maintains | Equal-Weight | Get Alert |
| 03/21/2025 | Buy Now | 29.74% | B of A Securities | Tazeen Ahmad55% | $302 → $325 | Maintains | Buy | Get Alert |
| 03/21/2025 | Buy Now | 19.76% | Chardan Capital | Keay Nakae54% | $300 → $300 | Maintains | Buy | Get Alert |
| 03/21/2025 | Buy Now | 27.74% | Needham | Joseph Stringer51% | $320 → $320 | Reiterates | Buy → Buy | Get Alert |
| 03/11/2025 | Buy Now | 11.78% | JP Morgan | Jessica Fye64% | $272 → $280 | Maintains | Neutral | Get Alert |
| 02/26/2025 | Buy Now | 23.75% | RBC Capital | Luca Issi39% | $310 → $310 | Reiterates | Outperform → Outperform | Get Alert |
| 02/26/2025 | Buy Now | 19.76% | Chardan Capital | Keay Nakae54% | $300 → $300 | Maintains | Buy | Get Alert |
| 02/26/2025 | Buy Now | 27.74% | Needham | Joseph Stringer51% | $320 → $320 | Reiterates | Buy → Buy | Get Alert |
| 02/25/2025 | Buy Now | 99.6% | HC Wainwright & Co. | Patrick Trucchio45% | $400 → $500 | Reiterates | Buy → Buy | Get Alert |
| 02/24/2025 | Buy Now | 99.6% | HC Wainwright & Co. | Patrick Trucchio45% | $400 → $500 | Maintains | Buy | Get Alert |
| 02/18/2025 | Buy Now | 53.69% | Canaccord Genuity | Whitney Ijem47% | $384 → $385 | Maintains | Buy | Get Alert |
| 02/14/2025 | Buy Now | 19.76% | Scotiabank | Greg Harrison43% | $310 → $300 | Maintains | Sector Outperform | Get Alert |
| 02/14/2025 | Buy Now | 13.37% | Morgan Stanley | Michael Ulz61% | $275 → $284 | Maintains | Equal-Weight | Get Alert |
| 02/14/2025 | Buy Now | 27.74% | Needham | Joseph Stringer51% | $320 → $320 | Reiterates | Buy → Buy | Get Alert |
| 02/11/2025 | Buy Now | 19.76% | RBC Capital | Luca Issi39% | $300 → $300 | Reiterates | Outperform → Outperform | Get Alert |
| 01/21/2025 | Buy Now | 19.76% | RBC Capital | Luca Issi39% | $300 → $300 | Reiterates | Outperform → Outperform | Get Alert |
| 01/13/2025 | Buy Now | 59.68% | HC Wainwright & Co. | Patrick Trucchio45% | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 01/13/2025 | Buy Now | 27.74% | Needham | Joseph Stringer51% | $320 → $320 | Reiterates | Buy → Buy | Get Alert |
| 01/07/2025 | Buy Now | 23.75% | Bernstein | William Pickering40% | $314 → $310 | Maintains | Outperform | Get Alert |
| 11/18/2024 | Buy Now | 18.16% | Piper Sandler | Edward Tenthoff52% | $296 → $296 | Reiterates | Overweight → Overweight | Get Alert |
| 11/18/2024 | Buy Now | 59.68% | HC Wainwright & Co. | Patrick Trucchio45% | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 11/12/2024 | Buy Now | — | Wolfe Research | Andy Chen40% | — | Downgrade | Peer Perform → Underperform | Get Alert |
| 11/04/2024 | Buy Now | 59.68% | HC Wainwright & Co. | Patrick Trucchio45% | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 11/01/2024 | Buy Now | 18.96% | Raymond James | Gary Nachman58% | $275 → $298 | Maintains | Outperform | Get Alert |
| 11/01/2024 | Buy Now | 19.76% | RBC Capital | Luca Issi39% | $300 → $300 | Reiterates | Outperform → Outperform | Get Alert |
| 11/01/2024 | Buy Now | 23.75% | Scotiabank | Greg Harrison43% | $305 → $310 | Maintains | Sector Outperform | Get Alert |
| 11/01/2024 | Buy Now | 31.34% | Barclays | Gena Wang50% | $295 → $329 | Maintains | Overweight | Get Alert |
| 11/01/2024 | Buy Now | 53.29% | Canaccord Genuity | Whitney Ijem47% | $366 → $384 | Maintains | Buy | Get Alert |
| 11/01/2024 | Buy Now | 19.76% | Chardan Capital | Keay Nakae54% | $300 → $300 | Maintains | Buy | Get Alert |
| 11/01/2024 | Buy Now | 27.74% | Needham | Joseph Stringer51% | $320 → $320 | Reiterates | Buy → Buy | Get Alert |
| 10/21/2024 | Buy Now | 48.1% | TD Cowen | Ritu Baral35% | $282 → $371 | Maintains | Buy | Get Alert |
| 10/18/2024 | Buy Now | 59.68% | HC Wainwright & Co. | Patrick Trucchio45% | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 10/16/2024 | Buy Now | 21.76% | Scotiabank | Greg Harrison43% | → $305 | Initiates | → Sector Outperform | Get Alert |
| 10/14/2024 | Buy Now | 25.35% | B of A Securities | Tazeen Ahmad55% | $307 → $314 | Maintains | Buy | Get Alert |
| 10/11/2024 | Buy Now | 19.76% | Chardan Capital | Keay Nakae54% | $300 → $300 | Maintains | Buy | Get Alert |
| 10/11/2024 | Buy Now | -12.18% | Cantor Fitzgerald | Olivia Brayer57% | $220 → $220 | Reiterates | Neutral → Neutral | Get Alert |
| 10/10/2024 | Buy Now | 19.76% | RBC Capital | Luca Issi39% | $300 → $300 | Reiterates | Outperform → Outperform | Get Alert |
| 10/10/2024 | Buy Now | 27.74% | Needham | Joseph Stringer51% | $320 → $320 | Reiterates | Buy → Buy | Get Alert |
| 09/19/2024 | Buy Now | 19.76% | RBC Capital | Luca Issi39% | $300 → $300 | Reiterates | Outperform → Outperform | Get Alert |
| 09/09/2024 | Buy Now | -12.18% | Cantor Fitzgerald | Olivia Brayer57% | $220 → $220 | Reiterates | Neutral → Neutral | Get Alert |
| 09/04/2024 | Buy Now | 19.76% | RBC Capital | Luca Issi39% | $300 → $300 | Reiterates | Outperform → Outperform | Get Alert |
| 09/04/2024 | Buy Now | 22.55% | B of A Securities | Tazeen Ahmad55% | $295 → $307 | Maintains | Buy | Get Alert |
| 08/30/2024 | Buy Now | 59.68% | HC Wainwright & Co. | Patrick Trucchio45% | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 08/26/2024 | Buy Now | 11.78% | JP Morgan | Jessica Fye64% | $248 → $280 | Maintains | Neutral | Get Alert |
| 08/20/2024 | Buy Now | 59.68% | HC Wainwright & Co. | Patrick Trucchio45% | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 08/16/2024 | Buy Now | 47.7% | Goldman Sachs | Salveen Richter53% | $198 → $370 | Upgrade | Neutral → Buy | Get Alert |
| 08/02/2024 | Buy Now | 19.76% | RBC Capital | Luca Issi39% | $265 → $300 | Maintains | Outperform | Get Alert |
| 08/02/2024 | Buy Now | -6.99% | Wells Fargo | Tiago Fauth43% | $207 → $233 | Maintains | Equal-Weight | Get Alert |
| 08/02/2024 | Buy Now | 9.78% | Raymond James | Gary Nachman58% | $208 → $275 | Maintains | Outperform | Get Alert |
| 08/02/2024 | Buy Now | -20.96% | Goldman Sachs | Salveen Richter53% | $174 → $198 | Maintains | Neutral | Get Alert |
| 08/02/2024 | Buy Now | 36.53% | Citigroup | David Lebovitz64% | $291 → $342 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 17.76% | Barclays | Gena Wang50% | $291 → $295 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | 46.11% | Canaccord Genuity | Whitney Ijem47% | $357 → $366 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 27.74% | Needham | Joseph Stringer51% | $275 → $320 | Maintains | Buy | Get Alert |
| 07/22/2024 | Buy Now | -12.18% | Cantor Fitzgerald | Olivia Brayer57% | $150 → $220 | Maintains | Neutral | Get Alert |
| 07/12/2024 | Buy Now | 1.8% | Morgan Stanley | Michael Ulz61% | $250 → $255 | Maintains | Equal-Weight | Get Alert |
| 07/08/2024 | Buy Now | 42.51% | Canaccord Genuity | Whitney Ijem47% | $283 → $357 | Maintains | Buy | Get Alert |
| 07/03/2024 | Buy Now | -1% | JP Morgan | Jessica Fye64% | $160 → $248 | Maintains | Neutral | Get Alert |
| 07/01/2024 | Buy Now | -40.12% | Cantor Fitzgerald | Olivia Brayer57% | $150 → $150 | Reiterates | Neutral → Neutral | Get Alert |
| 06/28/2024 | Buy Now | 14.97% | UBS | Eliana Merle43% | $253 → $288 | Maintains | Buy | Get Alert |
| 06/27/2024 | Buy Now | 5.79% | RBC Capital | Luca Issi39% | $250 → $265 | Maintains | Outperform | Get Alert |
| 06/27/2024 | Buy Now | 17.76% | Stifel | Paul Matteis41% | $215 → $295 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | 16.17% | Citigroup | David Lebovitz64% | $227 → $291 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | 17.76% | B of A Securities | — | $248 → $295 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | -36.53% | Leerink Partners | — | $138 → $159 | Maintains | Market Perform | Get Alert |
| 06/25/2024 | Buy Now | 12.57% | TD Cowen | Ritu Baral35% | $260 → $282 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | 3.79% | Evercore ISI Group | Liisa Bayko70% | $210 → $260 | Maintains | Outperform | Get Alert |
| 06/25/2024 | Buy Now | 16.17% | Barclays | Gena Wang50% | $236 → $291 | Maintains | Overweight | Get Alert |
| 06/25/2024 | Buy Now | -0.2% | RBC Capital | Luca Issi39% | $235 → $250 | Maintains | Outperform | Get Alert |
| 06/25/2024 | Buy Now | -17.37% | Wells Fargo | Tiago Fauth43% | $161 → $207 | Maintains | Equal-Weight | Get Alert |
| 06/25/2024 | Buy Now | -0.2% | Morgan Stanley | Michael Ulz61% | $164 → $250 | Maintains | Equal-Weight | Get Alert |
| 06/24/2024 | Buy Now | 9.78% | Needham | Joseph Stringer51% | $200 → $275 | Maintains | Buy | Get Alert |
| 06/24/2024 | Buy Now | 59.68% | HC Wainwright & Co. | Patrick Trucchio45% | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 06/24/2024 | Buy Now | -6.59% | BMO Capital | Kostas Biliouris32% | $234 → $234 | Maintains | Outperform | Get Alert |
| 06/21/2024 | Buy Now | 12.97% | Canaccord Genuity | Whitney Ijem47% | $283 → $283 | Maintains | Buy | Get Alert |
| 05/07/2024 | Buy Now | 59.68% | HC Wainwright & Co. | Patrick Trucchio45% | $395 → $400 | Maintains | Buy | Get Alert |
| 05/03/2024 | Buy Now | -10.18% | Chardan Capital | Keay Nakae54% | $225 → $225 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | -20.16% | Needham | Joseph Stringer51% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | -6.59% | BMO Capital | Kostas Biliouris32% | $234 → $234 | Maintains | Outperform | Get Alert |
| 03/05/2024 | Buy Now | 57.68% | HC Wainwright & Co. | Patrick Trucchio45% | $395 → $395 | Reiterates | Buy → Buy | Get Alert |
| 02/23/2024 | Buy Now | -40.12% | Cantor Fitzgerald | Olivia Brayer57% | $165 → $150 | Maintains | Neutral | Get Alert |
| 02/21/2024 | Buy Now | -6.19% | RBC Capital | Luca Issi39% | $235 → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/20/2024 | Buy Now | -6.19% | RBC Capital | Luca Issi39% | $235 → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/20/2024 | Buy Now | -34.13% | Cantor Fitzgerald | Olivia Brayer57% | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 02/16/2024 | Buy Now | -6.19% | RBC Capital | Luca Issi39% | $235 → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/16/2024 | Buy Now | -35.73% | Wells Fargo | Tiago Fauth43% | $171 → $161 | Maintains | Equal-Weight | Get Alert |
| 02/16/2024 | Buy Now | -9.38% | Citigroup | David Lebovitz64% | $237 → $227 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | -10.18% | Chardan Capital | Keay Nakae54% | $250 → $225 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | -30.94% | Goldman Sachs | Salveen Richter53% | $230 → $173 | Downgrade | Buy → Neutral | Get Alert |
FAQ
What is the target price for Alnylam Pharmaceuticals (ALNY) stock?
The latest price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) was reported by Morgan Stanley on April 11, 2025. The analyst firm set a price target for $268.00 expecting ALNY to rise to within 12 months (a possible 6.99% upside). 89 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Alnylam Pharmaceuticals (ALNY)?
The latest analyst rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) was provided by Morgan Stanley, and Alnylam Pharmaceuticals maintained their equal-weight rating.
When was the last upgrade for Alnylam Pharmaceuticals (ALNY)?
The last upgrade for Alnylam Pharmaceuticals Inc happened on March 24, 2025 when JP Morgan raised their price target to $328. JP Morgan previously had a neutral for Alnylam Pharmaceuticals Inc.
When was the last downgrade for Alnylam Pharmaceuticals (ALNY)?
The last downgrade for Alnylam Pharmaceuticals Inc happened on November 12, 2024 when Wolfe Research changed their price target from N/A to N/A for Alnylam Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Alnylam Pharmaceuticals (ALNY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alnylam Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alnylam Pharmaceuticals was filed on April 11, 2025 so you should expect the next rating to be made available sometime around April 11, 2026.
Is the Analyst Rating Alnylam Pharmaceuticals (ALNY) correct?
While ratings are subjective and will change, the latest Alnylam Pharmaceuticals (ALNY) rating was a maintained with a price target of $284.00 to $268.00. The current price Alnylam Pharmaceuticals (ALNY) is trading at is $250.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
